logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme Says EMA Accepts Oral Teriflunomide MAA To Treat Multiple Sclerosis

Genzyme, a Sanofi company (SNY), announced the European Medicines Agency, or EMA, has accepted the filing of the marketing authorization application, or MAA, for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis, or MS.

The company noted that the purpose of the MAA is to secure approval to market and allow prescription of teriflunomide in the European Union based on data from two completed pivotal Phase III trials, TEMSO and TENERE. These trials represent two of five efficacy studies of teriflunomide in MS that are completed or underway, making the clinical program one of the largest and broadest of any MS therapy in development.

An application to market teriflunomide in the United States is under review by the U.S. Food & Drug Administration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Mortgage rates are continuing to hold at low levels amidst ongoing economic uncertainty, mortgage provider Freddie Mac announced Thursday. The 30-year fixed-rate mortgage averaged 3.89% with an average 0.4 point during the week ending August 17, down from 3.90% in the prior week. It is now just one basis point above its 2017 low. Shares of Infosys Technologies Ltd. were losing around 10 percent in Indian trading on Friday after the Software exporter announced that Vishal Sikka has resigned as the Managing Director and Chief Executive Officer with immediate effect. The company appointed current chief operating officer Pravin Rao as the Interim-Managing Director and Chief Executive Officer. Reports that Gary Cohn is considering resigning as President Donald Trump's top economic advisor have weighed on Wall Street, although the White House has denied the claims. Cohn, former president and chief operating officer of Goldman Sachs (GS), currently serves as the Director of the National Economic Council.
comments powered by Disqus
Follow RTT